Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:59:58 PM EDT
135.18
+2.16 (+1.62%)
Products, Regulatory

Pharma Mar Starts Confirmatory Phase III Clinical Trial, Lagoon, Evaluating Zepzelca (Lurbinectedin) For Treatment Of Relapsed Small Cell Lung Cancer

Published: 12/13/2021 07:41 GMT
Jazz Pharmaceuticals plc (JAZZ) - Announces With Partner Jazz Pharmaceuticals, Initiation of Confirmatory Phase Iii Clinical Trial, Lagoon, Evaluating Zepzelca (lurbinectedin) for Treatment of Patients With Relapsed Small Cell Lung Cancer.
Confirmatory Trial is Designed to Secure Full Approval in U.S. and Serve As a Registrational Trial for European Medicines Agency.
Multi-center, Open-label Global Trial Will Enroll 705 Patients From Over 100 Centers Mainly in North America and Europe.